These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1449 related articles for article (PubMed ID: 28355305)

  • 1. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization combined with recombinant human adenovirus type¬†5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
    He CB; Lao XM; Lin XJ
    Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
    Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
    Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
    Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
    Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
    Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
    J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization.
    Fan W; Zhang Y; Wang Y; Yao X; Yang J; Li J
    PLoS One; 2015; 10(3):e0119312. PubMed ID: 25742141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI).
    Ji F; Liang Y; Fu SJ; Guo ZY; Shu M; Shen SL; Li SQ; Peng BG; Liang LJ; Hua YP
    BMC Cancer; 2016 Feb; 16():137. PubMed ID: 26907597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis.
    He C; Zhang Y; Lin X
    J Gastrointest Surg; 2018 Jun; 22(6):989-997. PubMed ID: 29435900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
    Pinato DJ; Sharma R
    Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC).
    Lin XJ; Li QJ; Lao XM; Yang H; Li SP
    BMC Cancer; 2015 Oct; 15():707. PubMed ID: 26470869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-lymphocyte Ratio Plus Prognostic Nutritional Index Predicts the Outcomes of Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization.
    Liu C; Li L; Lu WS; Du H; Yan LN; Yang JY; Wen TF; Zeng GJ; Jiang L; Yang J
    Sci Rep; 2017 Oct; 7(1):13873. PubMed ID: 29066730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma.
    Xu Y; Yuan X; Zhang X; Hu W; Wang Z; Yao L; Zong L
    Medicine (Baltimore); 2021 Jun; 100(25):e26506. PubMed ID: 34160470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization.
    Liu C; Li L; Lu WS; Du H; Yan LN; Wen TF; Wei WR; Jiang L; Xu MQ
    BMC Cancer; 2018 Feb; 18(1):216. PubMed ID: 29466970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study.
    Pang Q; Zhou L; Qu K; Cui RX; Jin H; Liu HC
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):60-70. PubMed ID: 29189392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.
    Liu J; Zhang W; Niu R; Li Y; Zhou X; Han X
    Saudi Med J; 2020 Apr; 41(4):376-382. PubMed ID: 32291424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
    Li L; Gou CY; Li JY; Achakzai R; Li XH
    Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation.
    Yang XG; Huang YC; Wang CH; Sun YY; Huang Z; Xu GH
    Cancer Invest; 2022 Jul; 40(6):494-504. PubMed ID: 35404178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation.
    Chu MO; Shen CH; Chang TS; Xu HW; Yen CW; Lu SN; Hung CH
    Sci Rep; 2018 Nov; 8(1):16611. PubMed ID: 30413724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.